GGB Awards Sponsor Spotlight: Aurobindo

With entries now closed for the Global Generics & Biosimilars Awards 2024, and submissions in the process of being evaluated by our expert judging panel – ahead of the prizegiving ceremony at the Hotel NH Milano Fiera on Wednesday 9 October, during CPhI Worldwide week – Generics Bulletin is bringing you profiles of our category sponsors this year.

Aurobindo, which has long been a supporter of the Global Generics & Biosimilars Awards, is this year sponsoring our Industry Partner Of The Year award, recognizing outstanding achievements by firms or individuals that work alongside generics and biosimilars manufacturers and suppliers.

Aurobindo, headquartered in India’s Hyderabad, is one of the largest generic pharmaceutical companies globally, with a presence in over 150 countries and ranking eighth in the most recent Generics Bulletin Top 50. (Also see "The Generics Bulletin Top 50, Part One: Top Ten Ranking Conceals Changes For Industry Leaders" - Generics Bulletin, 5 Aug, 2024.)

For the financial year ending 31 March 2024, the company reported “impressive” sales of INR290bn ($3.5bn), which Aurobindo said “reflected the company’s steadfast commitment to excellence and competitiveness in the global market”.

With around 90% of this sales figure generated from international markets, Aurobindo says it has “firmly set its sights on being a leading diversified and vertically integrated player by significant investment in complex formulations R&D, capacity expansion and diversifying its manufacturing base.”

“Aurobindo is a leading, well-integrated global pharmaceutical company, dedicated to making medicines affordable and accessible to patients worldwide,” the company tells Generics Bulletin. According to the firm, “our growth strategy focuses on diversifying our product pipeline, particularly in specialty and complex generics while leveraging  in-house development capabilities and strategic partnerships.”

The company is also advancing its biosimilars and vaccines development programs to meet evolving patient needs. Aurobindo has made significant investments in complex formulations R&D, capacity expansion, and diversification of its manufacturing base.

In addition to this, Aurobindo is focused on expanding its geographical presence and tapping into promising growth markets. The company has filed 830 abbreviated new drug applications in the US, securing a strong presence across various therapeutic categories. The company has also recently completed the construction of an oral formulations manufacturing facility in China, aimed to serve both European and Chinese markets.

“Aurobindo Pharma’s strategic priorities have centered on scaling up cost-effective manufacturing and expanding R&D efforts, particularly in new product categories including differentiated offerings,” said P V Ramprasad Reddy, founder of the company, in a discussion with Generics Bulletin. “We are dedicated to maintaining the highest standards of quality and compliance required by the regulators across geographies.”

“The growth trajectory led by increased sales stemming from new product launches, expansion into growth markets, and volume gains coupled with stable pricing, lays a robust foundation for the company’s future endeavors,” Aurobindo said. Over the next twelve months, the firm anticipates “a significant uptick in operational contributions from the manufacturing facilities including Pen-G, 6-APA, and injectables as these facilities ramp up their operations,” with the company summarizing that “this strong foundation positions Aurobindo for continued success in the global pharmaceutical industry”.

Echoing these goals, V Muralidharan, CEO of firm’s European business, emphasized the company’s strategic focus on “continuous innovation in product development, operational excellence and diversification into innovative product categories.”

“At the center of all we do is a deep commitment to patients, which drives our efforts to make available affordable medicines across the globe. We are proud to partner with the Global Generics & Biosimilars Awards which plays an important role in fostering collaboration across the generic pharmaceutical industry” Muralidharan added.

This year, Aurobindo’s sponsored Global Generics & Biosimilars Awards category of Industry Partner Of The Year will see judges choose between a range of firms adjacent to the generics, biosimilars and value added medicines sector.

For a full list of the awards categories, submissions criteria, how to attend and other information, go here.

To enquire about sponsorship opportunities, please e-mail [email protected]

And to register interest in attending the Global Generics & Biosimilars Awards 2024, to receive the latest updates and for any further details, please e-mail [email protected]